OBIO Valuation
Orchestra Biomed Holdings Inc
$
2.795
- Overview
- Forecast
- Valuation
OBIO Relative Valuation
OBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OBIO is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for OBIO's competitors is 22.14, providing a benchmark for relative valuation. Orchestra Biomed Holdings Inc Corp (OBIO) exhibits a P/S ratio of 28.93, which is 30.67% above the industry average. Given its robust revenue growth of 40.00%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
SLRN
ACELYRIN Inc
2.270
USD
+1.76%
BCBP
BCB Bancorp Inc
8.260
USD
-1.55%
SEVN
Seven Hills Realty Trust
11.720
USD
-1.51%
PESI
Perma-Fix Environmental Services Inc
10.250
USD
0.00%
BVFL
BV Financial Inc
15.750
USD
-0.16%
SWKH
SWK Holdings Corp
14.260
USD
0.00%
WRN
Western Copper and Gold Corp
1.155
USD
+1.32%
MAPS
WM Technology Inc
1.093
USD
-2.41%
ISTR
Investar Holding Corp
19.225
USD
-0.65%
BCOV
Brightcove Inc
4.450
USD
0.00%
FAQ
Is Orchestra Biomed Holdings Inc (OBIO) currently overvalued or undervalued?
Orchestra Biomed Holdings Inc (OBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 28.93 is considered Fairly compared with the five-year average of 57.10. The fair price of Orchestra Biomed Holdings Inc (OBIO) is between 0.86 to 9.06 according to relative valuation methord.
What is Orchestra Biomed Holdings Inc (OBIO) fair value?
How does OBIO's valuation metrics compare to the industry average?
What is the current P/B ratio for Orchestra Biomed Holdings Inc (OBIO) as of May 21 2025?
What is the current FCF Yield for Orchestra Biomed Holdings Inc (OBIO) as of May 21 2025?
What is the current Forward P/E ratio for Orchestra Biomed Holdings Inc (OBIO) as of May 21 2025?